Clinical trials: Management of investigational products during the COVID-19 pandemic

Laurent Flet; Martine Tching-Sin; Adeline Chanat; Pauline Gendre; Annick Tibi

doi:10.1093/ajhp/zxaa146

Clinical trials: Management of investigational products during the COVID-19 pandemic

Am J Health Syst Pharm. 2020 Aug 7;77(16):1277-1278. doi: 10.1093/ajhp/zxaa146.

Authors

Laurent Flet¹, Martine Tching-Sin¹, Adeline Chanat¹, Pauline Gendre¹, Annick Tibi²

Affiliations

¹ Department of Pharmacy Nantes University Hospital Nantes, France.
² Agence Générale des Equipements et Produits de Santé Hôpitaux de Paris, France.

Abstract

Disclaimer: In an effort to expedite the publication of articles related to the COVID-19 pandemic, AJHP is posting these manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.

Keywords: COVID-19; clinical trials; investigational drugs.

MeSH terms

Antiviral Agents / therapeutic use*
COVID-19
Clinical Trials as Topic*
Coronavirus Infections / drug therapy*
Documentation
Drugs, Investigational*
Humans
Pandemics*
Pneumonia, Viral / drug therapy*

Substances

Antiviral Agents
Drugs, Investigational